Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
|Articles|October 1, 1999
Supplements and Featured Publications
- The Appropriate Use of Antibiotic Therapy
- Volume 5
- Issue 15 Suppl
Diagnosis and Management of Group A Streptococcal Pharyngitis: A Practice Guideline
Advertisement
Articles in this issue
almost 27 years ago
Participating Facultyalmost 27 years ago
Introductionalmost 27 years ago
Drug Resistance and the Treatment of Upper Respiratory Infectionsalmost 27 years ago
CME Quizalmost 27 years ago
BibliographyAdvertisement
Related to this article
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
5